World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF THYROID CANCER USING SIMILAR MOLECULE SORAFENIB BETA-D-GLUCURONIDE

Dr. Syed Ahmed Hussain*, Nazneen, Faheem Unnisa, Arshiya Tarannum, Umaima Batool Osmani, Raheem Unnisa Shaik and Maimuna Fatima

ABSTRACT

Aim: This study aims to evaluate the potential of Sorafenib beta-D-Glucuronide, a molecular analog of Sorafenib,
as an alternative treatment for thyroid cancer, particularly in cases where the conventional drug Lenvatinib has
limited effectiveness. Objective: To compare the cytotoxic effects of Sorafenib beta-D-Glucuronide with
Lenvatinib using various cell viability assays, including MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH
Cytotoxicity assays. Research: Thyroid cancer cells were treated with varying concentrations of Sorafenib beta-DGlucuronide
(1, 5, and 10 μM), and their viability was measured. The MTT, CellTiter-Glo, and Alamar Blue
assays showed a consistent reduction in cell viability with increasing concentrations, indicating a dose-dependent
cytotoxic effect. The SRB assay showed similar trends, though with slight variations, while the LDH Cytotoxicity
assay confirmed cell damage and death. Conclusion: Sorafenib beta-D-Glucuronide demonstrated significant
cytotoxic activity against thyroid cancer cells, comparable to Lenvatinib, and could be explored further as a
therapeutic alternative. Future studies should focus on its in vivo efficacy and safety to establish its clinical
potential.

[Full Text Article]   [Download Certificate]